GOVERNMENT SOLUTIONS

Modernizing federal health data with IQVIA's experts

IQVIA transforms fragmented data into unified insights for faster decisions, measurable equity outcomes, and life-saving crisis response. Make a positive impact at the local or national level using leading-edge technology and deep domain expertise.
Trust is only built via transformative results
When Hurricane Maria struck, HHS needed medication intelligence within minutes, not days. When FDA required vaccine safety surveillance, accuracy meant lives. These aren't hypotheticals. They're real partnerships where IQVIA delivered when it mattered most. See how we've helped agencies like yours achieve their missions.

The Global Use of Medicines 2022

In this report, we examine the spending and usage of medicines in 2021 and the outlook to 2026, globally and for specific therapy areas and countries. We intend this report to provide a foundation for meaningful discussion about the value, cost and role of medicines over the next five years in the context of overall healthcare spending.

Are you prepared for tomorrow's global health crisis?

Stay ahead with a systematic approach to global health. This research outlines how to address challenges through concerted action and shared responsibility.

NONCOMMUNICABLE DISEASES ARE KILLERS
71%

Deaths worldwide are caused by noncommunicable diseases, like heart and respiratory conditions.

Source Coming Together to Address Global Health Priorities - April 2025
PEOPLE LIVING IN FRAGILE SETTINGS
1.8 B

People live in fragile settings with suboptimal healthcare capacity to support appropriate care.

Source Coming Together to Address Global Health Priorities - April 2025
CLIMATE CHANGE AND HUMAN HEALTH
1 in 4

Deaths can be attributed to climate change or preventable environmental causes.

Source Coming Together to Address Global Health Priorities - April 2025

Ready to transform federal health data?

Your agency's mission demands modern solutions. Let's discuss how IQVIA can help you achieve faster insights, measurable equity outcomes, and crisis-ready infrastructure. Our federal team understands your requirements and timeline.

Real-time surveillance detected vaccine safety signals in record time

Overview

When the FDA needed to monitor COVID-19 vaccine safety across millions of Americans, traditional surveillance methods weren't fast enough. The CBER BEST Initiative required a partner who could analyze massive insurance claims data in near real-time to detect rare adverse events. IQVIA Government Solutions' surveillance system continuously monitored 17 adverse events among 15 million vaccinated individuals, providing critical safety insights to inform regulatory decisions.

The team implemented Poisson Maximized Sequential Probability Ratio Testing to compare observed versus expected outcome rates, enabling early detection of safety signals invisible in pre-licensure trials. Within months of vaccine rollout, the system identified elevated myocarditis/pericarditis rates in young men following mRNA vaccination.

 

This finding, published in The Lancet, represented one of the largest observational vaccine studies conducted at the time. By processing over 27 million vaccine doses across multiple insurance databases, IQVIA helped CBER make evidence-based regulatory decisions while vaccines were being administered nationwide. The surveillance system's ability to stratify risk by age, sex, and vaccine type allowed for targeted safety communications and informed clinical guidance, demonstrating how real-world data can enhance public health decision-making during critical moments.

Challenge

Monitor rare vaccine adverse events across millions of recipients in near real-time during emergency authorization period.
Solution

Federated data network analyzed 27+ million doses using sequential hypothesis testing to detect safety signals.
Results

Published peer-reviewed safety findings that shaped FDA regulatory decisions and clinical guidance.
Contact Us